Poliomyelitis as a paradigm for investment in and success of vaccination programs

Pediatric Infectious Disease Journal

Volumn 18, Issue 1, 1999, Pages 10-15

  Ogra, Pearay L ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Poliomyelitis; Vaccination programs

Indexed keywords

POLIOMYELITIS VACCINE;

COST BENEFIT ANALYSIS; HEALTH CARE DELIVERY; HISTORY; HUMAN; IMMUNIZATION; INFECTION CONTROL; INFECTION RISK; NOTE; POLIOMYELITIS; PRIORITY JOURNAL; VACCINE PRODUCTION;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; RISK ASSESSMENT; UNITED STATES; WORLD HEALTH;

EID: 0032960313     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199901000-00004     Document Type: Note

References (32)

1. Poliomyelitis: annual statistical review. White Plains, NY: The National Foundation, 1961.
2. Paul JR. Clinical epidemiology. Chicago: University of Chicago Press, 1958:204-20.
3. Surveillance of poliomyelitis in the United States 1958-1964. Public Health Rep 1962;77:1011-20.
4. The changing status of polio: progress in health services. Health Information Found 1959;8:1-6.
5. Harrington H. Review of literature. In: Internatal Committee for the Study of Infantile Paralysis, eds. Poliomyelitis: a survey made possible by a grant from the International Committee for the Study of Infantile Paralysis. Baltimore: Williams & Wilkins, 1932:130-44.
6. What you should know about poliovaccine. The National Foundation. Publication No. 19, 1962.
7. Kolmer JA, Klugh G Jr, Rule AM. A successful method for vaccination against acute anterior poliomyelitis, for the report. JAMA 1935;104:456-60.
8. Brodie M, Park WH. Active immunization against poliomyelitis. Am J Public Health 1936;26:119-25.
9. Smith JS. Patenting the sun: polio and Salk vaccine. New York: Anchor Books Doubleday, 1991.
10. Bodian D. Differentiation of types of poliomyelitis viruses: I. Reinfection experiments in monkeys (second attacks). Am J Hyg 1949;49:200-24.
11. Morgan IM. Immunization of monkeys with formalin-inactivated poliomyelitis viruses. Am J Hyg 1948;48:394-406.
12. Enders JF, Weller TH, Robinson FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949;109:85-7.
13. Enders JF. General preface to studies on the cultivation of poliomyelitis viruses in tissue culture. J Immunol 1952;69: 639-43.
14. Salk JE. Principles of immunization as applied to poliomyelitis and influenza. Am J Public Health 1953;43:1384-2398.
15. Koprowski H, Jervis GA, Norton TW. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis virus. Am J Hyg 1952;55:109-26.
16. Sabin AB. Characteristics and genetic potentialities of experimentally reproduced and naturally occurring variants of poliomyelitis virus. Ann NY Acad Sci 1955;61:924-38.
17. The economic significance of the prevention of paralytic poliomyelitis 1955-1961. In: The report of the Commission on the Cost of Medical Care. chap 4. American Medical Association, 1964:29-46.
18. Berkovich S, Pickering JE, Kibrick S. Paralytic poliomyelitis in Massachusetts: a study of the disease in a well vaccinated population. N Engl J Med 1959;264:1323-6.
19. Gresham GE. Epidemic of type 3 paralytic poliomyelitis in Baltimore, Maryland, 1960. Public Health Rep 1962;77:349.
20. Bodian D. Poliomyelitis immunization: mass use of oral vaccine in the United States might prevent definitive evaluation of either vaccine. Science 1961;134:819.
21. Ogra PL, Karzon D. Formation and function of poliovirus antibody in different tissues. Prog Med Virol 1971;13:156-93.
22. Hinman AR, Koplan JP, Orenstein WA, Brick EW, Nkowane BM. Live or inactivated poliomyelitis vaccine: an analysis of benefits and risk. Am J Pub Health 1988;78:291-5.
23. Poliomyelitis [Letter]. Lancet 1963;2:632.
24. Ogra P, Faden H. Poliovirus vaccines: live or dead. J Pediatr 1986;108:1031-3.
25. CDC certification of poliomyelitis eradication in the Americas. MMWR 1994;54:720-2.
26. Progress towards global poliomyelitis eradication 1985-1994. MMWR 1995;44:273-81.
27. CDC Mass vaccination with oral poliovirus vaccine: Asia and Europe. MMWR 1995;44:234-6.
28. Landauer KS, Stickle G. An analysis of residual disabilities (paralysis and crippling) among 100 000 poliomyelitis patients with special reference to the rehabilitation of past poliomyelitis patients. Arch Phys Med Rehab 1958;39:141-51.
29. Bart K, Foulds J, Patriarca P. The global eradication of poliomyelitis: benefit-cost analysis. Bull World Health Organ 1996;74:35-45.
30. Abraham R, Minor P, Dunn G, Modlin JF, Ogra PL. Shedding of virulent poliovirus revertants during immunization with oral poliovaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993;168:1105-9.
31. Plotkin SA. Inactivated polio vaccine for the United States: a missed vaccination opportunity. Pediatr Infect Dis J 1995;14: 835-9.
32. Faden H, Modlin JF, Thomas ML, McBean AM, Ferndon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent polio virus vaccines in childhood: systemic and local immune response. J Infect Dis 1990;162:1291-7.